Research programme: PAR-1 antagonists - Merck
Alternative Names: Research programme: thrombin receptor antagonists - Schering-Plough; SCH 205831; SCH 602539Latest Information Update: 04 Nov 2017
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class
- Mechanism of Action PAR 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
- 02 Apr 2009 Preclinical development is ongoing in the US with the orally administered PAR-1 antagonists (237th American Chemical Society National Meeting (237th-ACS-2009))